Characterisation of infantile cardiomyopathy in Alström syndrome using ALMS1 knockout induced pluripotent stem cell derived cardiomyocyte model.

ALMS1 Alström syndrome Cardiomyopathy Characterisation iPSC

Journal

Molecular genetics and metabolism
ISSN: 1096-7206
Titre abrégé: Mol Genet Metab
Pays: United States
ID NLM: 9805456

Informations de publication

Date de publication:
02 Sep 2024
Historique:
received: 17 07 2024
revised: 27 08 2024
accepted: 31 08 2024
medline: 8 9 2024
pubmed: 8 9 2024
entrez: 7 9 2024
Statut: aheadofprint

Résumé

Alström syndrome (AS) is an inherited rare ciliopathy characterised by multi-organ dysfunction and premature cardiovascular disease. This may manifest as an infantile-onset dilated cardiomyopathy with significant associated mortality. An adult-onset restrictive cardiomyopathy may also feature later in life. Loss of function pathogenic variants in ALMS1 have been identified in AS patients, leading to a lack of ALMS1 protein. The biological role of ALMS1 is unknown, particularly in a cardiovascular context. To understand the role of ALMS1 in infantile cardiomyopathy, the reduction of ALMS1 protein seen in AS patients was modelled using human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs), in which ALMS1 was knocked out. MuscleMotion analysis and calcium optical mapping experiments suggest that ALMS1 knockout (KO) cells have increased contractility, with altered calcium extrusion and impaired calcium handling dynamics compared to wildtype (WT) counterparts. Seahorse metabolic assays showed ALMS1 knockout iPSC-CMs had increased glycolytic and mitochondrial respiration rates, with ALMS1 knockout cells portraying increased energetic demand and respiratory capacity than WT counterparts. Using senescence associated β-galactosidase (SA-β gal) staining assay, we identified increased senescence of ALMS1 knockout iPSC-CMs. Overall, this study provides insights into the molecular mechanisms in AS, particularly the role of ALMS1 in infantile cardiomyopathy in AS, using iPSC-CMs as a 'disease in a dish' model to provide insights into multiple aspects of this complex disease.

Identifiants

pubmed: 39243575
pii: S1096-7192(24)00459-1
doi: 10.1016/j.ymgme.2024.108575
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108575

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare no conflict of interest.

Auteurs

Leena Patel (L)

Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK. Electronic address: LXP062@student.bham.ac.uk.

Ashwin Roy (A)

Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK; Department of Cardiology, Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, Birmingham, UK.

Jonathan Barlow (J)

Cellular Health and Metabolism Facility, School of Sport, Exercise and Rehabilitation, University of Birmingham, Birmingham, UK.

Christopher O'Shea (C)

Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.

Daniel Nieves (D)

Institute of Immunology and Immunotherapy, University of Birmingham, UK.

Amar J Azad (AJ)

Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK; Center of Biological Design, Berlin Institute of Health at Charité, Universitätsmedizin Berlin, Berlin, Germany.

Caitlin Hall (C)

Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.

Ben Davies (B)

Genetic Modification Service, The Francis Crick Institute, London, UK; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.

Phalguni Rath (P)

Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.

Davor Pavlovic (D)

Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.

Ashish Chikermane (A)

Paediatric Cardiology, Birmingham Children's Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, Birmingham, UK.

Tarek Geberhiwot (T)

Department of Inherited Metabolic Diseases, University Hospital Birmingham NHS Foundation Trust, Birmingham, Birmingham, UK; Institute of Metabolism and System Research, University of Birmingham, Birmingham, UK.

Richard P Steeds (RP)

Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK; Department of Cardiology, Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, Birmingham, UK.

Katja Gehmlich (K)

Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK; Division of Cardiovascular Medicine, Radcliffe Department of Medicine and British Heart Foundation Centre of Research Excellence Oxford, University of Oxford, Oxford, UK. Electronic address: k.gehmlich@bham.ac.uk.

Classifications MeSH